{"id":4460,"date":"2026-10-12T08:33:30","date_gmt":"2026-10-12T08:33:30","guid":{"rendered":"https:\/\/nhdbio.com\/?p=4460"},"modified":"2026-10-12T08:33:30","modified_gmt":"2026-10-12T08:33:30","slug":"calendriers-de-transfert-du-produit-medicamenteux-a-base-de-peptide-api","status":"publish","type":"post","link":"https:\/\/nhdbio.com\/fr\/peptide-api-drug-product-handover-timelines\/","title":{"rendered":"De l'API peptidique \u00e0 la formulation clinique : pourquoi les transferts peuvent retarder un projet"},"content":{"rendered":"<div class=\"nhd-news-lesson\">\n<figure class=\"cover\"><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/10\/nhd-news-20261012-28.webp\" alt=\"Themed illustration of the handover process from research to production\" width=\"1672\" height=\"941\"><figcaption>Editorial illustration, not an experimental photograph.<\/figcaption><\/figure>\n<p class=\"lead\">Once a peptide is synthesized, there may still be considerable work before it enters clinical use. The PepCellerate program introduced by CordenPharma places raw material and formulation development in a tighter process, aiming to reduce exactly the time lost to repeated handovers between different teams.<\/p>\n<section class=\"section\" id=\"section-1\">\n<h2>First distinguish raw material and formulation<\/h2>\n<p>Peptide raw material is the active pharmaceutical ingredient, while formulation turns it into a final form suitable for research or clinical use. A qualified raw material does not mean that work on sterile formulation, stability, or packaging has already been completed.<\/p>\n<p>Raw material development and formulation development involve different work. When discussing time and cost, listing the two parts separately makes it possible to know how far the current work has progressed and what is still missing afterward.<\/p>\n<aside class=\"helper\" aria-label=\"Reading aid diagram\">\n<div class=\"helper-title\">Raw material and formulation developed separately<\/div>\n<div class=\"steps\">\n<div class=\"step\"><strong>Peptide raw material<\/strong><small>Identity, process, and analysis<\/small><\/div>\n<p><span class=\"arrow\" aria-hidden=\"true\">\u2192<\/span><\/p>\n<div class=\"step\"><strong>Formulation development<\/strong><small>Formulation, stability, and packaging<\/small><\/div>\n<p><span class=\"arrow\" aria-hidden=\"true\">\u2192<\/span><\/p>\n<div class=\"step\"><strong>Delivery at the corresponding stage<\/strong><small>Confirmation of quality and regulatory conditions<\/small><\/div>\n<\/div>\n<p class=\"helper-note\">Work content diagram, not a commitment to NHD clinical formulation development capability or delivery.<\/p>\n<\/aside>\n<\/section>\n<section class=\"section\" id=\"section-2\">\n<h2>What duplicate work can handovers cause?<\/h2>\n<p>When changing teams or locations, process, analytical methods, quality information, and samples need to be transferred. If methods are understood differently, repeated testing, re-adjustment of conditions, or waiting for confirmation may occur.<a class=\"source-ref\" href=\"#sources\" aria-label=\"View original source\">[1]<\/a><\/p>\n<p>This kind of waiting does not necessarily come from slow synthesis. Sometimes the reaction has already finished, yet the project is still stuck at the interface among materials, data, and responsibilities.<\/p>\n<\/section>\n<section class=\"section\" id=\"section-3\">\n<h2>What approach did the company propose?<\/h2>\n<p>A technical article dated September 28 introduced more coordinated raw material and formulation development, project management, and parallel arrangements. Its idea is to reduce unnecessary transfers and complete required work in advance at the appropriate stage.<a class=\"source-ref\" href=\"#sources\" aria-label=\"View original source\">[1]<\/a><\/p>\n<p>&quot;Parallel&quot; also does not mean everything starts at the same time. Some steps must depend on the results of the previous step; for example, only after sample identity is confirmed do subsequent data have clear meaning.<\/p>\n<\/section>\n<section class=\"section\" id=\"section-4\">\n<h2>About 11 months, and this needs to be read together with the applicable conditions<\/h2>\n<p>The approximately 11 months given in the article applies to specific project conditions, including within about 40 to 45 amino acids, a batch range of 50 to 600 grams, and so on, and does not apply to all complex peptides.<\/p>\n<p>It belongs to the company&#039;s platform and project description. It cannot be directly treated as a guarantee for all suppliers or all clinical candidates, and even less as a quoted delivery time for NHD.<\/p>\n<\/section>\n<section class=\"section\" id=\"section-5\">\n<h2>How can rework later be avoided during the research stage?<\/h2>\n<p>From the beginning, record the sequence, termini, modifications, salt form, and analytical methods clearly, and keep traceable batch records. If a higher-quality stage is considered later, discuss additional requirements as early as possible.<\/p>\n<p>Research samples do not need to pretend to already be clinical formulations, but basic identity and method information should be clear. This lets future teams know what the material in hand actually is and reduces re-guessing.<\/p>\n<\/section>\n<section class=\"section\" id=\"section-6\">\n<h2>Does the research stage need to complete all commercialization work?<\/h2>\n<p>It is not necessary to complete the furthest stage all at once, but the current material identity, batch, and analysis should be traceable. Then discuss additional requirements based on what stage comes next, avoiding doing a lot of inapplicable work in advance.<\/p>\n<p>You can keep a project checklist: what has been confirmed, what is still missing, and who is responsible. Using the same document for verification during handover is easier to keep consistent than having different teams each rewrite their own explanation.<\/p>\n<\/section>\n<aside class=\"takeaway\"><strong>Remember this point when reading this article<\/strong><\/p>\n<p>Delivery time depends not only on synthesis but also on the handover of data, samples, and methods between teams; about 11 months has clear applicable conditions.<\/p>\n<\/aside>\n<section class=\"materials\" id=\"materials\">\n<div class=\"eyebrow\">Related research materials<\/div>\n<h2>View materials and analytical information<\/h2>\n<p class=\"materials-intro\">Custom peptide services can be used to communicate research sample and analytical requirements. If clinical or GMP needs are involved, project scope, qualifications, and delivery conditions should be confirmed separately.<\/p>\n<div class=\"product-grid\">\n<article class=\"product-card\">\n<div class=\"card-head\">\n<div>\n<div class=\"product-label\">Sequence, modifications, and analytical requirements<\/div>\n<h3>Custom peptide services<\/h3>\n<\/div>\n<\/div>\n<div class=\"card-body\">\n<p>Explain the required sequence, terminal form, quantity, and testing requirements, and confirm the delivery scope according to the project.<\/p>\n<p><a href=\"https:\/\/nhdbio.com\/services\/custom-peptide-synthesis\/\" target=\"_blank\" rel=\"noopener\">Learn about custom services \u2192<\/a><\/div>\n<\/article>\n<\/div>\n<\/section>\n<section class=\"sources\" id=\"sources\">\n<h2>Original materials<\/h2>\n<div>Material date: 2026-09-28 \u00b7 Third-party process and project management introduction<\/div>\n<ul>\n<li><a href=\"https:\/\/cordenpharma.com\/articles\/accelerate-peptide-therapeutic-time-to-clinical-phase-1-with-pepcellerate-first-in-human\/\" target=\"_blank\" rel=\"noopener\">Original announcement\/research release page \u2197<\/a><\/li>\n<\/ul>\n<\/section>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Une fois un peptide synth\u00e9tis\u00e9, il peut encore rester un travail consid\u00e9rable avant son entr\u00e9e en usage clinique. Le programme PepCellerate introduit par CordenPharma place le d\u00e9veloppement des mati\u00e8res premi\u00e8res et de la formulation dans un processus plus resserr\u00e9, visant \u00e0 r\u00e9duire pr\u00e9cis\u00e9ment le temps perdu lors des transferts r\u00e9p\u00e9t\u00e9s entre diff\u00e9rentes \u00e9quipes.<\/p>","protected":false},"author":1,"featured_media":4459,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"pim_family_ids":"","pim_article_type":"Manufacturing and research methods","pim_evidence_level":"Third-party process and project management introduction","pim_reviewer":"AI-assisted source and editorial check","pim_reviewed_date":"2026-10-12","pim_editorial_note":"Original public sources, study populations and limitations are linked. Editorial illustrations are not experimental photographs.","pim_review_status":"reviewed","pim_review_reason":"Reviewed Chinese source, protected scientific values and links, unique illustration, related product families and responsive layout checked.","pim_creation_method":"AI-assisted writing","pim_sources":"[{\"title\":\"Research news reference \u2014 cordenpharma.com \u2014 news-28\",\"note\":\"\",\"url\":\"https:\/\/cordenpharma.com\/articles\/accelerate-peptide-therapeutic-time-to-clinical-phase-1-with-pepcellerate-first-in-human\/\"}]","footnotes":""},"categories":[20],"tags":[],"class_list":["post-4460","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-evidence-quality-guides"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.0 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>From peptide API to clinical formulation: why handovers can delay a project | NHD<\/title>\n<meta name=\"description\" content=\"Once a peptide is synthesized, there may still be considerable work before it enters clinical use. The PepCellerate program introduced by CordenPharma places raw material and formulation development in a tighter process, aiming to reduce exactly the time lost to repeated handovers between different teams.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/fr\/calendriers-de-transfert-du-produit-medicamenteux-a-base-de-peptide-api\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"From peptide API to clinical formulation: why handovers can delay a project\" \/>\n<meta property=\"og:description\" content=\"Once a peptide is synthesized, there may still be considerable work before it enters clinical use. The PepCellerate program introduced by CordenPharma places raw material and formulation development in a tighter process, aiming to reduce exactly the time lost to repeated handovers between different teams.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/fr\/calendriers-de-transfert-du-produit-medicamenteux-a-base-de-peptide-api\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-12T08:33:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/10\/nhd-news-20261012-28.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1672\" \/>\n\t<meta property=\"og:image:height\" content=\"941\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"NHD Technical Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"NHD Technical Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/peptide-api-drug-product-handover-timelines\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/peptide-api-drug-product-handover-timelines\\\/\"},\"author\":{\"name\":\"NHD Technical Team\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\"},\"headline\":\"From peptide API to clinical formulation: why handovers can delay a project\",\"datePublished\":\"2026-10-12T08:33:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/peptide-api-drug-product-handover-timelines\\\/\"},\"wordCount\":711,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/peptide-api-drug-product-handover-timelines\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/nhd-news-20261012-28.webp\",\"articleSection\":[\"Evidence &amp; Quality Guides\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/peptide-api-drug-product-handover-timelines\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/peptide-api-drug-product-handover-timelines\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/peptide-api-drug-product-handover-timelines\\\/\",\"name\":\"From peptide API to clinical formulation: why handovers can delay a project | NHD\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/peptide-api-drug-product-handover-timelines\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/peptide-api-drug-product-handover-timelines\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/nhd-news-20261012-28.webp\",\"datePublished\":\"2026-10-12T08:33:30+00:00\",\"description\":\"Once a peptide is synthesized, there may still be considerable work before it enters clinical use. The PepCellerate program introduced by CordenPharma places raw material and formulation development in a tighter process, aiming to reduce exactly the time lost to repeated handovers between different teams.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/peptide-api-drug-product-handover-timelines\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/peptide-api-drug-product-handover-timelines\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/peptide-api-drug-product-handover-timelines\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/nhd-news-20261012-28.webp\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/nhd-news-20261012-28.webp\",\"width\":1672,\"height\":941,\"caption\":\"Themed illustration of the handover process from research to production\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/peptide-api-drug-product-handover-timelines\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"From peptide API to clinical formulation: why handovers can delay a project\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\",\"name\":\"NHD Technical Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"caption\":\"NHD Technical Team\"},\"description\":\"NHD Technical Team maintains research-use catalog documentation and evidence summaries. Reviewed articles link to peer-reviewed papers, trial registries and regulatory records, retain null findings and study limitations, and distinguish published interventions from catalog materials. AI-assisted drafting may be used for structure; source links and evidence boundaries remain visible. This work is not independent peer review or medical advice.\",\"sameAs\":[\"https:\\\/\\\/nhdbio.com\"],\"url\":\"https:\\\/\\\/nhdbio.com\\\/fr\\\/author\\\/qianmiao-technical-team\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"De l'API peptidique \u00e0 la formulation clinique : pourquoi les transferts peuvent retarder un projet | NHD","description":"Une fois un peptide synth\u00e9tis\u00e9, il peut encore rester un travail consid\u00e9rable avant son entr\u00e9e en usage clinique. Le programme PepCellerate introduit par CordenPharma place le d\u00e9veloppement des mati\u00e8res premi\u00e8res et de la formulation dans un processus plus resserr\u00e9, visant \u00e0 r\u00e9duire pr\u00e9cis\u00e9ment le temps perdu lors des transferts r\u00e9p\u00e9t\u00e9s entre diff\u00e9rentes \u00e9quipes.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/fr\/calendriers-de-transfert-du-produit-medicamenteux-a-base-de-peptide-api\/","og_locale":"fr_FR","og_type":"article","og_title":"From peptide API to clinical formulation: why handovers can delay a project","og_description":"Once a peptide is synthesized, there may still be considerable work before it enters clinical use. The PepCellerate program introduced by CordenPharma places raw material and formulation development in a tighter process, aiming to reduce exactly the time lost to repeated handovers between different teams.","og_url":"https:\/\/nhdbio.com\/fr\/calendriers-de-transfert-du-produit-medicamenteux-a-base-de-peptide-api\/","og_site_name":"NHD","article_published_time":"2026-10-12T08:33:30+00:00","og_image":[{"width":1672,"height":941,"url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/10\/nhd-news-20261012-28.webp","type":"image\/webp"}],"author":"NHD Technical Team","twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","twitter_misc":{"\u00c9crit par":"NHD Technical Team","Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nhdbio.com\/peptide-api-drug-product-handover-timelines\/#article","isPartOf":{"@id":"https:\/\/nhdbio.com\/peptide-api-drug-product-handover-timelines\/"},"author":{"name":"NHD Technical Team","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1"},"headline":"From peptide API to clinical formulation: why handovers can delay a project","datePublished":"2026-10-12T08:33:30+00:00","mainEntityOfPage":{"@id":"https:\/\/nhdbio.com\/peptide-api-drug-product-handover-timelines\/"},"wordCount":711,"commentCount":0,"publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"image":{"@id":"https:\/\/nhdbio.com\/peptide-api-drug-product-handover-timelines\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/10\/nhd-news-20261012-28.webp","articleSection":["Evidence &amp; Quality Guides"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/nhdbio.com\/peptide-api-drug-product-handover-timelines\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/peptide-api-drug-product-handover-timelines\/","url":"https:\/\/nhdbio.com\/peptide-api-drug-product-handover-timelines\/","name":"De l'API peptidique \u00e0 la formulation clinique : pourquoi les transferts peuvent retarder un projet | NHD","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nhdbio.com\/peptide-api-drug-product-handover-timelines\/#primaryimage"},"image":{"@id":"https:\/\/nhdbio.com\/peptide-api-drug-product-handover-timelines\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/10\/nhd-news-20261012-28.webp","datePublished":"2026-10-12T08:33:30+00:00","description":"Une fois un peptide synth\u00e9tis\u00e9, il peut encore rester un travail consid\u00e9rable avant son entr\u00e9e en usage clinique. Le programme PepCellerate introduit par CordenPharma place le d\u00e9veloppement des mati\u00e8res premi\u00e8res et de la formulation dans un processus plus resserr\u00e9, visant \u00e0 r\u00e9duire pr\u00e9cis\u00e9ment le temps perdu lors des transferts r\u00e9p\u00e9t\u00e9s entre diff\u00e9rentes \u00e9quipes.","breadcrumb":{"@id":"https:\/\/nhdbio.com\/peptide-api-drug-product-handover-timelines\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/peptide-api-drug-product-handover-timelines\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/nhdbio.com\/peptide-api-drug-product-handover-timelines\/#primaryimage","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/10\/nhd-news-20261012-28.webp","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/10\/nhd-news-20261012-28.webp","width":1672,"height":941,"caption":"Themed illustration of the handover process from research to production"},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/peptide-api-drug-product-handover-timelines\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"From peptide API to clinical formulation: why handovers can delay a project"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"Mati\u00e8res premi\u00e8res peptidiques et synth\u00e8se sur mesure","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1","name":"\u00c9quipe technique NHD","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","caption":"NHD Technical Team"},"description":"L'\u00e9quipe technique NHD maintient la documentation du catalogue d'utilisation de la recherche et les r\u00e9sum\u00e9s des preuves. Les articles examin\u00e9s renvoient \u00e0 des articles \u00e9valu\u00e9s par des pairs, \u00e0 des registres d'essais et \u00e0 des dossiers r\u00e9glementaires, conservent les r\u00e9sultats nuls et les limites des \u00e9tudes, et distinguent les interventions publi\u00e9es des documents du catalogue. Le dessin assist\u00e9 par AI peut \u00eatre utilis\u00e9 pour la structure\u00a0; les liens vers les sources et les limites des preuves restent visibles. Ce travail ne constitue pas un examen ind\u00e9pendant par des pairs ni un avis m\u00e9dical.","sameAs":["https:\/\/nhdbio.com"],"url":"https:\/\/nhdbio.com\/fr\/author\/qianmiao-technical-team\/"}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/posts\/4460","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/comments?post=4460"}],"version-history":[{"count":3,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/posts\/4460\/revisions"}],"predecessor-version":[{"id":4463,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/posts\/4460\/revisions\/4463"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/media\/4459"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/media?parent=4460"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/categories?post=4460"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/tags?post=4460"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}